Skip to main content

Table 3 Univariate and multivariate analyses of risk factors for regimen change in the CKD patients

From: Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease

  Regimen change Univariate Multivariate
Yes No Odds ratio 95% CI P value Odds ratio 95% CI P value
n = 25 n = 129
 Male, n (%) 12 (48.0%) 78 (60.5%) 0.60 0.26–1.43 0.250 1.94 0.55–6.85 0.305
 BMI, kg/m2 (mean ± SD) 19.1 ± 2.60 19.0 ± 2.66 1.01 0.86–1.19 0.858    
CKD severity
 Mild 10 (40.0%) 83 (64.3%) Reference Reference
 Moderate 9 (36.0%) 34 (26.4%) 2.20 0.82–5.88 0.117 2.10 0.57–7.71 0.264
 Severe 6 (24.0%) 12 (9.3%) 4.15 1.28–13.5 0.018 5.92 1.08–32.5 0.041
Underlying disease
 Liver damage 2 (8.0%) 10 (7.8%) 1.03 0.21–5.04 0.966    
Laboratory data
 Albumin, g/dL (mean ± SD) 2.6 ± 0.8 3.2 ± 0.8 0.41 0.23–0.73 0.003 0.68 0.31–1.46 0.320
Treatment regimen, n (%)
 HREZ 13 (52.0%) 76 (58.9%) 0.755 0.32–1.78 0.523    
Adverse events
 Drug-induced hepatitis, n (%) 14 (56.0%) 8 (6.2%) 19.3 6.63–55.9 <0.001 35.6 8.70–145 <0.001
 Cutaneous reaction, n (%) 6 (24.0%) 5 (3.9%) 7.83 2.17–28.2 0.002 17.4 3.16–95.5 0.001
  1. BMI body mass index, CI confidence interval, CKD chronic kidney disease, HREZ isoniazid, rifampicin, ethambutol and pyrazinamide, SD standard deviation